Fennec Pharmaceuticals Inc.
FENC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $47,538 | $21,252 | $1,474 | $0 |
| % Growth | 123.7% | 1,341.6% | – | – |
| Cost of Goods Sold | $3,184 | $1,259 | $83 | $0 |
| Gross Profit | $44,354 | $19,993 | $1,392 | $0 |
| % Margin | 93.3% | 94.1% | 94.4% | – |
| R&D Expenses | $307 | $56 | $3,391 | $4,937 |
| G&A Expenses | $23,053 | $20,585 | $0 | $0 |
| SG&A Expenses | $41,479 | $32,708 | $19,694 | $12,134 |
| Sales & Mktg Exp. | $18,426 | $12,123 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $41,786 | $32,764 | $23,086 | $17,071 |
| Operating Income | $2,568 | -$12,771 | -$21,694 | -$17,071 |
| % Margin | 5.4% | -60.1% | -1,471.6% | – |
| Other Income/Exp. Net | -$2,639 | -$3,274 | -$1,080 | -$122 |
| Pre-Tax Income | -$71 | -$16,045 | -$22,774 | -$17,193 |
| Tax Expense | $365 | $0 | $0 | $0 |
| Net Income | -$436 | -$16,045 | -$22,774 | -$17,193 |
| % Margin | -0.9% | -75.5% | -1,544.9% | – |
| EPS | -0.016 | -0.6 | -0.95 | -0.67 |
| % Growth | 97.3% | 36.8% | -41.8% | – |
| EPS Diluted | -0.016 | -0.6 | -0.95 | -0.67 |
| Weighted Avg Shares Out | 27,294 | 26,574 | 26,275 | 26,006 |
| Weighted Avg Shares Out Dil | 27,294 | 26,574 | 26,275 | 26,006 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,593 | $441 | $195 | $54 |
| Interest Expense | $4,069 | $3,394 | $978 | $126 |
| Depreciation & Amortization | $800 | $287 | $0 | $0 |
| EBITDA | $4,798 | -$12,364 | -$21,692 | -$17,068 |
| % Margin | 10.1% | -58.2% | -1,471.5% | – |